About Careers MedBlog Contact us

Swiss Drug Maker May Formulate Drugs for Alzheimer's After Results from Competitor

by Julia Samuel on April 24, 2015 at 11:31 AM
Font : A-A+

Swiss Drug Maker May Formulate Drugs for Alzheimer's After Results from Competitor

Roche, the Swiss drug maker is optimistic about formulating drugs for Alzheimer's disease after it received promising results with a similar product from Biogen, a competitor.

Daniel O'Day, Pharmaceuticals head, said that Roche would look again at prospects for two of its experimental Alzheimer's drugs, which suffered setbacks in 2014, in the wake of recent data on Biogen's drug.


Alzheimer's medicine, aducanumab in a small trial showed a significantly slowed cognitive impairment in patients with mild symptoms, which is a rare bit of good news in the midst of high-profile failures from the likes of Pfizer and Eli Lilly.

Aducanumab similar to Roche's experimental product gantenerumab, blocks beta amyloid, a protein that forms toxic brain plaques, the underlying cause of Alzheimer's. Yet the results presented in Biogen's trial contrasts with a late-stage Phase III study with gantenerumab and Roche's Phase II drug crenezumab.

"We're not at a stage where we've made a final decision on those two programs, but we're encouraged because the data that was presented from Biogen showed a concordance between dose level, between plaque removal and between clinical effect," said O'Day.

Current drugs prescribed for Alzheimer's can do no more than ease some of the symptoms rather than delaying the progression of Alzheimer's unlike heart disease and cancer, which have seen major strides in drug development.

Source: Medindia


Recommended Reading

Latest Drug News

AstraZeneca's Liver Cancer Drug Approved by CDSCO in India
The CDSCO has approved the intravenous administration of AstraZeneca Pharma India's liver cancer drug, Tremelimumab Concentrate.
 FDA Issues Warning About Compounded Diabetes Drug Semaglutide Products
The FDA advises consumers not to use compounded medications as an alternative to known diabetic and weight reduction medications Ozempic, Rybelsus, and Wegovy.
 Parkinson's Unmet Needs Creates Path for New Entrants into the Market
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
How Microrobots Could Help Treat Bladder Diseases?
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
How Can Multivitamin Supplements Slow Cognitive Aging?
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Swiss Drug Maker May Formulate Drugs for Alzheimer's After Results from Competitor Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests